PRECLINICAL REPORTSResponse to immunotherapy rechallenge after interval chemotherapy in a patient with head and neck cancerCabezas-Camarero, Santiagoa; Cabrera-Martín, María N.b; Pérez-Segura, PedroaAuthor Information Departments of aMedical Oncology bNuclear Medicine, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico Universitario San Carlos, Madrid, Spain Correspondence to Santiago Cabezas-Camarero, MD, Department of Medical Oncology, Centro de Investigación en Red de Cáncer (CIBERONC), Hospital Clínico Universitario San Carlos, Madrid, 28040 Spain Tel: +34 913 303 000 ×2667; fax: +34 913 303 544; e-mail: [email protected] Received May 29, 2018 Accepted October 2, 2018 Anti-Cancer Drugs: February 2019 - Volume 30 - Issue 2 - p 149-152 doi: 10.1097/CAD.0000000000000706 Buy Metrics Abstract Patients with metastatic squamous cell cancer of the head and neck (SCCHN) have a poor prognosis, with most patients surviving less than a year. Immunotherapy (IO) is changing the natural history of the disease and programmed death-ligand 1 (PD-L1) inhibitors are showing notable improvements in survival with a more favourable toxicity profile than chemotherapy. To our knowledge, there are no data regarding how checkpoint blockade inhibitors may behave at rechallenge in SCCHN. We present the case of a metastatic hypopharyngeal cancer patient who after progressing clinically and radiologically to PD-L1-based IO and then to second-line cetuximab-based chemotherapy, achieved a partial response to third-line nivolumab. Our case shows that PD(L)1 rechallenge after interval chemotherapy may be worth considering in SCCHN. Studies should try to address which is the optimal treatment sequence in the era of IO in SCCHN. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.